Head-to-head · WeighScore
Boston Medical Group vs Vytora Health
The verdict
Vytora Health takes it — 72.3/100 to 61.9/100.
Vytora Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vytora Health is a 50-state-plus-DC telehealth platform offering compounded semaglutide and tirzepatide alongside brand-name Mounjaro and Zepbound, plus NAD+ and sermorelin peptides.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | Vytora Health |
|---|---|---|
| WeighScore | 61.9/100 | 72.3/100 |
| Grade | C | C |
| Scorecard rank | #279 | #79 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | $180/mo (all doses, compounded) |
| Tirzepatide | Not disclosed | $249/mo (all doses, compounded) |
| Coverage | 7 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #79 · C
Strengths
- All 50 states plus DC, with per-state video-vs-audio compliance disclosed
- Both compounded and brand-name options on one platform — uncommon
- LegitScript Approved and HIPAA compliant
- Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
- Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)
Where it loses points
- Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
- Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
- Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
- Initial consultation cost not shown on the public pricing page
- Limited per-prescriber state licensure detail
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.